Background:
In recent years, the incidence of IBS has gradually increased, and it is considered as one of the most common functional gastrointestinal diseases. However, the etiology of IBS is still unclear, and expectations are rising for more targeted treatments. Many clinical trials have explored the link between
Helicobacter pylori
(
H pylori
) and IBS, with different conclusions. Therefore, we conducted a meta-analysis to explore whether there is an association between
H pylori
and IBS, which is of great significance for targeted treatment of IBS.
Methods:
We performed a systematic review and meta-analysis of the association between
H pylori
and IBS. We searched PubMed, EMBASE, Medline and the Cochrane Library to collect related studies. OR was used to describe the ratio of the probability of the
H pylori
infection occurring in IBS patients versus the controls. Heterogeneity was assessed by subgroup and meta-regression analysis.
Results:
Eight studies, including 1861 patients, assessed the association between
H pylori
infection and IBS. The OR of
H pylori
in IBS patients compared to controls was 1.32 (95% CI: 0.94–1.87; P = 0.11). Subgroup analyses showed a difference between IBS patients diagnosed with Roman III criteria and those diagnosed with non-Roman III criteria.
Conclusions:
Our study suggests that
H pylori
may have a positive effect on the development of IBS. Although the differences were not statistically significant, there were significant differences among subgroups of patients. Considering the limitations and heterogeneity, high quality studies are needed to further explore the effect of
H pylori
on the development of IBS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.